Hims & Hers Health reported fourth-quarter earnings of $0.08 per diluted share, a decrease from $0.11 in the prior year, though this figure exceeded analyst expectations of $0.04.
Revenue for the quarter also saw an increase. The company issued guidance for the first quarter that fell short of Wall Street's expectations, indicating a potential slowdown in growth compared to prior periods.
Recent analyst actions include Deutsche Bank adjusting its price target to $25 from $31 while maintaining a hold rating, and Truist Securities lowering its price target to $18 from $37, also maintaining a hold rating. The stock experienced a slight decrease in after-hours trading.
Data sourced from public RSS feeds and News APIs.